veski innovation fellow
Peter MacCallum Cancer Centre
Professor Mark Dawson was awarded the 3-year veski innovation fellowship in March 2014.
Professor Dawson is one of Australia’s most promising and talented clinician-researchers specialising in the fields of haematology and epigenetics. The high quality of his research is evidenced by the significant project grants and personal fellowships he has secured and the variety of publications and invitations to present at international conferences.
Research project: Targeting epigenetic readers in acute myeloid leukaemia
Epigenetics is one of the most active topics in cancer research with the potential to deliver a significant impact on a disease like acute myeloid leukaemia (AML), which has a very poor prognosis.
Current chemotherapies and supportive care still fail to cure the majority of patients with AML, and more than 70 per cent of patients still succumb to the heterogeneous disease, which is driven by various acquired mutations in the DNA of blood cells. A new approach is urgently required.
Epigenetic therapies which target proteins that package and regulate DNA have shown remarkable promise in the treatment of AML. Associate Professor Dawson’s project aims to study the most common subtype of AML and establish a novel targeted epigenetic therapy against this disease.
Epigenetics broadly describes the study of chromatin biology. Chromatin, a complex made up of DNA and histone proteins, provides the context for the regulation of all DNA templated processes such as transcription, repair and replication. Therefore mutations in chromatin/epigenetic regulators may induce and/or maintain various cancers including AML.
The dynamic plasticity of the epigenome lends itself well to therapeutic manipulation and Dr Dawson has recently demonstrated this process with a small molecule (IBET151) that inhibits the bromodomain and extra terminal (BET) family of proteins. These chromatin ‘reader’ proteins survey the epigenetic landscape and function as transcriptional co-activators.
Mark will build on these initial studies, aiming to translate important basic science discoveries made in the laboratory into innovative and targeted cancer therapies at the Peter MacCallum Cancer Centre and will build on previous collaborations with international pharmaceutical company GlaxoSmithKline.
Mark Dawson – veski announcement profile
Targeting epigenetic readers in acute myeloid leukaemia
Mark Dawson – veski announcement video
veski innovation fellow 2014
veski fellows in the media – accolades and achievements
Portraits of innovation (Part 4)
See the making of 5 portraits of veski innovation fellows: Dr Luke Connal, Professor Colette McKay, Dr Ethan Goddard-Borger, Dr Mark Dawson & Professor Kenneth Crozier